Entera Bio (ENTX) CEO Jayne Toledano Receives Option Awards

What Happened
Jayne Toledano, CEO of Entera Bio Ltd. (ENTX), was granted two option awards on August 7, 2026 totaling 700,000 options (500,000 and 200,000). The reported grant price is $0.00 (derivative awards), meaning no cash was paid at grant and these are stock option awards rather than purchases of shares.

Key Details

• Transaction date: 2026-08-07 (reported on Form 4, accession 0001178913-26-003950). Transaction code: A (award/grant).
• Awards: 500,000 options (F1) and 200,000 options (F2); aggregate = 700,000 options. Reported price per share: $0.00 (derivative).
• Vesting:
  • 500,000-option award (F1): Approved May 7, 2026; shareholder approval July 14, 2026; S-8 registration filed Aug 7, 2026. Vests over 3 years starting May 7, 2026 — 1/3 on May 7, 2027, remainder vesting quarterly over the next 2 years; full acceleration on a Change in Control per the Plan.
  • 200,000-option award (F2): Originally approved July 15, 2022 with shareholder approval Sept 7, 2022; became effective upon a Triggering Event satisfied by the July 2026 financing and S-8 filing on Aug 7, 2026. Vests over 4 years beginning Aug 7, 2026 — 25% after one year, remainder vesting quarterly over the next 3 years.
• Shares owned after transaction: Not specified in the provided Form 4 details.
• Filing timeliness: Reported on Aug 7, 2026 with the transaction date the same day; no late filing indicator noted.

Context
These filings report option grants (not exercises or open-market purchases). No shares were purchased or sold at the time of the grant; the awards give the right to buy ordinary shares in the future according to the vesting schedules. The grants were subject to prior board/shareholder approvals and required the company’s S-8 registration to be effective, which was completed on Aug 7, 2026.